Apellis Pharmaceuticals, Inc. $APLS Shares Acquired by Cwm LLC

Cwm LLC increased its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 29.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,584 shares of the company’s stock after acquiring an additional 29,326 shares during the period. Cwm LLC’s holdings in Apellis Pharmaceuticals were worth $2,208,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Woodline Partners LP grew its holdings in shares of Apellis Pharmaceuticals by 15.5% in the 1st quarter. Woodline Partners LP now owns 218,850 shares of the company’s stock worth $4,786,000 after acquiring an additional 29,373 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Apellis Pharmaceuticals by 43.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after acquiring an additional 30,507 shares during the period. Cerity Partners LLC grew its holdings in shares of Apellis Pharmaceuticals by 16.7% in the 1st quarter. Cerity Partners LLC now owns 54,444 shares of the company’s stock worth $1,191,000 after acquiring an additional 7,777 shares during the period. GAMMA Investing LLC grew its holdings in shares of Apellis Pharmaceuticals by 1,795.4% in the 1st quarter. GAMMA Investing LLC now owns 10,235 shares of the company’s stock worth $224,000 after acquiring an additional 9,695 shares during the period. Finally, Bayforest Capital Ltd grew its holdings in Apellis Pharmaceuticals by 431.9% during the 1st quarter. Bayforest Capital Ltd now owns 52,338 shares of the company’s stock valued at $1,145,000 after buying an additional 42,499 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $24.52 on Friday. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $35.72. The stock’s fifty day simple moving average is $25.38 and its 200-day simple moving average is $21.17. The company has a quick ratio of 3.16, a current ratio of 3.77 and a debt-to-equity ratio of 2.90. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -13.47 and a beta of 0.69.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The business had revenue of $171.39 million for the quarter, compared to analysts’ expectations of $187.91 million. During the same quarter last year, the firm earned ($0.30) earnings per share. The business’s revenue was down 10.6% on a year-over-year basis. Equities research analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Citigroup increased their target price on Apellis Pharmaceuticals from $41.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Cantor Fitzgerald increased their target price on Apellis Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Raymond James Financial lowered their target price on Apellis Pharmaceuticals from $52.00 to $50.00 and set an “outperform” rating on the stock in a report on Friday, August 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $33.47.

Insider Transactions at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $25.22, for a total value of $126,100.00. Following the transaction, the general counsel directly owned 113,730 shares of the company’s stock, valued at approximately $2,868,270.60. This trade represents a 4.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Cedric Francois sold 49,963 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $28.39, for a total value of $1,418,449.57. Following the completion of the transaction, the chief executive officer directly owned 307,946 shares in the company, valued at $8,742,586.94. This trade represents a 13.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 302,921 shares of company stock worth $8,210,566 over the last quarter. 6.50% of the stock is currently owned by insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).